Detection of Bcl-2 translocation in pancreatic cancer in Iranian patients

Gordehie, Susan; Sheikhnejad, Reza; Abdolhamid Angaji, Seyed; Khanaki, Mahmoud; Marandi, Vahid

Document Type : Original Article

Authors

¹ MSc. in Genetics, Kharazmi University, Karaj, Iran

² Ph.D. in Biochemistry, Biology Dept. Manager, Tofigh Daru Engineering-Research Co., Tehran, Iran

³ Assistant Professor, Department of Cell and Molecular biology, Faculty of Biological Sciences, Kharazmi University, Karaj, Iran

⁴ Associate Professor, Tehran University of Medical Sciences, Tehran, Iran

⁵ Validation Specialist, Production-Research Complex, Pasteur Institute of Iran, Karaj, Iran

Abstract

Background and Purpose: Pancreatic cancer is one of the most leading causes of cancer-related deaths. Considering the role of Bcl-2 family gene in apoptosis that are known to be over-expressed in most cancers, this study focused on the detection of Bcl-2 translocation t(14;18) to the immunoglobulin heavy chain (IgH) that may contribute to the pathogenesis of pancreatic cancer.
Materials and Methods: Forty-nine samples of paraffin embedded tissues (extracted from 1537 slides of 105 patients in one of the major local cancer centers) were investigated for detection of Bcl-2 translocation t(14;18) by standard PCR.
Results: The Bcl-2 t(14;18) translocation was detected in 23 of all 49 patients (46.9%), including 10 of 23 translocated patients (43%) with break points within the mbr cluster, 11 with involvement of the mcr locus (48%), and 2 in the icr locus (9%).
Discussion: Detection of Bcl2 translocation in pancreatic cancer is in agreement with results from other studies, and shows this rearrangement could be considered as a new treatment strategy based on apoptosis or personalized treatment.

Keywords: apoptosis, Bcl-2 translocation, pancreatic cancer,paraffin embedded tissue, personalized treatment, polymerase chain reaction.

Keywords

References

[1] Horvitz HR. Why does programmed cell death, or apoptosis, occur? Scientific American. 1999 Oct. 21, 1.

[2] Azmi AS, Mohammad RM. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J. Cell Physiol. 2009; 218: 13-21.

[3] Abraham DJ. Burger's medicinal chemistry and drug discovery. Wiley Online Library. 2003.

[4] Westphal S, Kalthoff H. Apoptosis: targets in pancreatic cancer. Molecular Cancer. 2003; 2(1): 6.

[5] Hamilton SR, Aaltonen LA. Cancer, International Agency for Research on, & Organization, World Health. Pathology and genetics of tumours of the digestive system. IARC press Lyon. 2000; 48.

[6] Delpu YH, Naïma L, Hubert S, Flavie S, Janick BL, Cordelier P. Genetic and epigenetic alterations in pancreatic carcinogenesis. Current Genomics. 2011; 12(1): 15.

[7] Kelekar A, Thompson CB. Bcl-2-family proteins: the role ofthe BH3 domain. Apoptosis Trends in Cell Biology. 1998; 8(8): 324-330

[8] Azmi AS, Mohammad RM. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J. Cell Physiol. 2009; 218: 13-21.

[9] Masood A, Azmi AS, Mohammad RM. Small molecule inhibitors of Bcl-2 family proteins for pancreatic cancer therapy. Cancers. 2011; 3(2): 1527-1549.

[10] Albinger-Hegyi A, Hochreutener B, Abdou MTh, Hegyi I, Dours-Zimmermann MT, Kurrer, Michael O Zimmermann DR. High frequency of t (14; 18)-translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas: improved polymerase chain reaction protocolsfor their detection. The American Journal of Pathology. 2002; 160(3): 823-832.

[11] Chan WC, Hawley RC. Practical detection of t(14; 18) (IgH/BCL-2) in follicular lymphoma. Archives of Pathology & Laboratory Medicine. 2008; 132(8): 1355

[12] Jalali N, MR Davati A, Tavakoli A. Expression of Bcl-2 gene in primary breast cancer and its correlation with some prognostic factors. J Mazandaran Univ Med Sci. 2007; 17(58): 30-36.

[13] Akl H, Vervloessem T, Kiviluoto S, Bittremieux M, Parys JB, De Smedt H, Bultynck G. A dual role for the anti-apoptotic Bcl-2 protein in cancer: Mitochondria versus endoplasmic reticulum. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2014; 1843(10): 2240-2252.

[14] Pikor LA, Enfield KS, Cameron H, Lam WL. DNA extraction from paraffin embedded material for genetic and epigenetic analyses. J Vis Exp. 2011; 49.

[15] Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008; 27(50): 6398-6406.

[16] Wallace DJ, Shen D, Reed GF, Miyanaga M, Mochizuki M, Sen HN, Chan Ch. Detection of the bcl-2 t(14; 18) translocation and proto-oncogene expression in primary intraocular lymphoma. Investigative Ophthalmology & Visual Science. 2006; 47(7): 2750.

[17]Yanai S, Nakamura S, Takeshita M, Fujita K, Hirahashi M, Kawasaki K, Matsumoto T. Translocation t (14; 18)/IGH-BCL2 in gastrointestinal follicular lymphoma. Cancer. 2011; 117(11): 2467-2477.

[18] Kirkin V, Joos S, Zörnig M. The role of Bcl-2 family members in tumorigenesis. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2004; 1644(2): 229-249.

[19] Ilievska PB, Smickova S, Jovanovska Crvenkovska S, Zafirovska Ivanovska B, Stefanovski T, Petrusevska G. Bcl-2 as a prognostic factor for survival in small-cell lung cancer. Contributions, Sec. Biol. Med. Sci., MASA, 2008; XXIX(2): 281-293.

Journal of Sabzevar University of Medical Sciences

Detection of Bcl-2 translocation in pancreatic cancer in Iranian patients

References

References

Volume 25, Issue 1
May and June 2018
Pages 60-68

Detection of Bcl-2 translocation in pancreatic cancer in Iranian patients

References

References

Volume 25, Issue 1May and June 2018Pages 60-68

Volume 25, Issue 1
May and June 2018
Pages 60-68